Coumatetralyl
Coumatetralyl
|
Names |
IUPAC name
(RS)-2-Hydroxy-3-(1,2,3,4-tetrahydronaphthalen-1-yl)-4H-chromen-4-one |
Identifiers |
|
5836-29-3 Y |
ChemSpider |
10468736 Y |
InChI=1S/C19H16O3/c20-18-15-9-3-4-11-16(15)22-19(21)17(18)14-10-5-7-12-6-1-2-8-13(12)14/h1-4,6,8-9,11,14,20H,5,7,10H2 YKey: ULSLJYXHZDTLQK-UHFFFAOYSA-N YInChI=1/C19H16O3/c20-18-15-9-3-4-11-16(15)22-19(21)17(18)14-10-5-7-12-6-1-2-8-13(12)14/h1-4,6,8-9,11,14,20H,5,7,10H2 Key: ULSLJYXHZDTLQK-UHFFFAOYAA
|
Jmol-3D images |
Image |
KEGG |
C16806 Y |
PubChem |
22095 |
OC=1c4ccccc4OC(=O)C=1C3CCCc2ccccc23
|
Properties |
Molecular formula |
C19H16O3 |
Molar mass |
292.33 g·mol−1 |
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) |
Y verify (what is: Y/N?) |
Infobox references |
|
|
Coumatetralyl is an anticoagulant of the 4-hydroxycoumarin vitamin K antagonist type. Symptoms of overexposure relate to failure of the blood clotting mechanism and include bleeding gums and failure of blood clotting after skin wounds. After one exposure the toxicity of coumatetralyl is relatively low, however if overexposure continues for several days the product becomes more toxic. The product must therefore be constantly present in the bloodstream for more than 1 to 2 days in order to be highly toxic. A single exposure, even though relatively large, may not produce toxic symptoms as the compound is quite rapidly metabolised. Chronic animal studies show no evidence of carcinogenic or teratogenic effects.
Common applications
Coumatetralyl is commonly used with grains and other cereals as a rodent poison in conjunction with a tracking powder to monitor feeding activity in a particular area. Tracking powder also clings to fur, which allows more poison to be ingested from grooming. Concentrations of the chemical are usually 500 mg per 1 kg of bait.
Rat poison grains
Treatment
Vitamin K1 (phylloquinone) is antidotal.
|
---|
| Antiplatelet drugs | | |
---|
| | |
---|
| | |
---|
| | |
---|
| Thromboxane inhibitors |
- Thromboxane synthase inhibitors
- Receptor antagonists
|
---|
| | |
---|
| Other | |
---|
|
---|
| Anticoagulants | | |
---|
| Factor Xa inhibitors (with some II inhibition) | |
---|
| | |
---|
| Other | |
---|
|
---|
| Thrombolytic drugs/ fibrinolytics | |
---|
| Non-medicinal | |
---|
| |
---|
| Description |
- Immune system
- Cells
- Physiology
- coagulation
- proteins
- granule contents
- colony-stimulating
- heme and porphyrin
|
---|
| Disease |
- Red blood cell
- Monocyte and granulocyte
- Neoplasms and cancer
- Histiocytosis
- Symptoms and signs
- Blood tests
|
---|
| Treatment |
- Transfusion
- Drugs
- thrombosis
- bleeding
- other
|
---|
|
|
|
---|
| Aglycones |
|
---|
| glycosides | |
---|
| derivatives | | Aglycones |
|
---|
| Furanocoumarin glycosides | |
---|
| Meroterpene furanocoumarin ether | |
---|
|
---|
|
---|
| Oligomers | |
---|
| Synthetic | |
---|
|